This regimen was first evaluated in the DECODE trial sponsored by PanACEA. Trial began in 2021.
Regimen
Delpazolid, Bedaquiline, Delamanid, & Moxifloxacin
Compounds in Regimen
Description
Trial Associations
Developer Associations